A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study

Purpose. To assess the safety profile of ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration (nAMD) in routine clinical practice. Methods. This 2-year, multicentre, observational study was conducted to capture real-world early practice and outcomes across Europe, shortly...

Full description

Saved in:
Bibliographic Details
Main Authors: Sergio Pagliarini, Stephen Beatty, Blandina Lipkova, Eduardo Perez-Salvador Garcia, Stefaan Reynders, Margarita Gekkieva, Abdelkader Si Bouazza, Stefan Pilz
Format: Article
Language:English
Published: Wiley 2014-01-01
Series:Journal of Ophthalmology
Online Access:http://dx.doi.org/10.1155/2014/857148
Tags: Add Tag
No Tags, Be the first to tag this record!